EGFR and lung adenocarcinoma: A retrospective study showed that (27), for NSCLC patients with EGFR mutations and brain metastases, there was no significant difference in OS between first-line Afatinib treated with brain radiation therapy (GKS or WBRT) and Afatinib alone (35.6 months vs 31.4 months, P=0.58), which was similar to the results of another previous retrospective study on Afatinib combined with WBRT compared with Afatinib alone in patients with brain metastasis of EGFR mutant lung adenocarcinoma (28).